Medication
Saxenda is daily liraglutide approved for chronic weight management in 2014, the original FDA-approved GLP-1 weight-loss product. Largely supplanted by weekly semaglutide and tirzepatide for new starts.
| Generic name | liraglutide |
| Brand manufacturer | Novo Nordisk |
| FDA indication | Chronic weight management |
| FDA approval year | 2014 |
| Form | Subcutaneous injection (prefilled pen) |
| Schedule | Daily |
| List price (cash) | $1349/month |
For drug-class comparisons, see our medication-comparison hub:
Coverage varies significantly by carrier and employer plan. See our insurance hub for plan-specific guidance:
Saxenda is the brand name for liraglutide, manufactured by Novo Nordisk. Saxenda is daily liraglutide approved for chronic weight management in 2014, the original FDA-approved GLP-1 weight-loss product. Largely supplanted by weekly semaglutide and tirzepatide for new start
Saxenda list price is approximately $1349/month. Insurance may cover it with prior authorization for FDA-approved indications.
FDA-approved 2014. Indication: Chronic weight management.
Doses available: 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3 mg. Schedule: Daily. Always follow your prescribing clinician's titration plan.
See our medication comparisons hub for head-to-head pages on Wegovy vs Zepbound, Ozempic vs Wegovy, and semaglutide vs tirzepatide.
Note: This page is an editorial overview, not medical advice. Always consult a licensed clinician about whether Saxenda is appropriate for you.